Files and links (1)
Published, Version of Record (VoR)Open Access (License Unspecified), Open
Journal article
Levetiracetam: A Practical Option for Seizure Management in Elderly Patients With Cognitive Impairment
American journal of Alzheimer's disease and other dementias, v 25(2), pp 149-154
01 Mar 2010
PMID: 19001351
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Cognitive impairment and seizures are common in our aging population. Anticonvulsant treatment is problematic due to sedation, cognitive slowing, and behavioral changes. Levetiracetam has favorable pharmacokinetics, good efficacy in elderly individuals, a favorable side effect profile, and lacks major drug interactions. We conducted a prospective, uncontrolled, phase 4, open label, 12-week study of levetiracetam to better profile its efficacy, safety, and impact on cognitive/behavioral status in 24 cognitively impaired, elderly individuals. In total, 69% were seizure free for the duration of the study; the remaining participants had satisfactory seizure control. Fatigue was the most common side effect (5 participants). Significant overall improvements were observed for the Folstein's Mini-Mental State Examination and the Alzheimer's Disease Assessment Scale-Cognitive. No significant changes were seen in behavioral or functional measures. Levetiracetam is an effective antiepileptic drug in elderly individuals with cognitive impairment. At 3 months, participants who remained on levetiracetam showed excellent cognitive tolerability.
Metrics
Details
- Title
- Levetiracetam: A Practical Option for Seizure Management in Elderly Patients With Cognitive Impairment
- Creators
- Carol F. Lippa - Drexel UniversityAndrea Rosso - Drexel UniversityMarjorie Hepler - Drexel UniversitySigmund Jenssen - Drexel UniversityJyoti Pillai - Drexel UniversityDavid Irwin - Drexel University
- Publication Details
- American journal of Alzheimer's disease and other dementias, v 25(2), pp 149-154
- Publisher
- Sage
- Number of pages
- 6
- Grant note
- UCB Pharma; UCB Pharma SA
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Neurology
- Web of Science ID
- WOS:000275177700009
- Scopus ID
- 2-s2.0-77749251909
- Other Identifier
- 991019167612504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Clinical Neurology
- Geriatrics & Gerontology